














486Blood and Gastric FOXP31 T Cells Are Not Decreased
in Human Gastric Graft-versus-Host Disease
James D. Lord,1,6,7 Robert C. Hackman,2,3,5,6 Ted A. Gooley,5 Brent L. Wood,3
Amanda C. Moklebust,6 David M. Hockenbery,1,4,5,6 Gideon Steinbach,1,5,6
Steven F. Ziegler,4,7 George B. McDonald1,5,6Previous studies suggest regulatory T cells (Tregs) inhibit graft-versus-host disease (GVHD) in mouse and
human hematopoietic cell transplant (HCT) recipients. As the gastrointestinal tract represents one of the
most common and severe sites of GVHD-related tissue damage, we sought to determine whether a deficit
in circulating or gastric mucosal Treg numbers correlates with the clinical onset of gastric GVHD. We used
the marker FOXP3 to quantify Tregs in blood and in gastric antral biopsies in a cohort of 60 allogeneic HCT
recipients undergoing endoscopy at a single center to evaluate symptoms suspicious for gastrointestinal
GVHD. We show for the first time in the gastric mucosa and, contrary to existing reports, in the blood,
that the percent of T cells expressing FOXP3 is at least as high in the presence as in the absence of
GVHD involving the upper gut. There was no correlation of Treg frequency with the histologic or clinical
severity of gastrointestinal GVHD. We conclude that Treg depletion is not a central feature in the pathogen-
esis of gastric GVHD in humans.
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Graft-versus-host disease (GVHD) of the gastroin-
testinal tract represents one of the most serious and
limiting complications of allogeneic hematopoietic
cell transplantation (HCT) [1]. The pathogenesis of
this disorder involves donor T cell recognition of host
minor or major histocompatibility antigens, resulting
in T cell activation, inflammation, and ultimately the
destruction of such host tissues as gastrointestinal
mucosa, skin, and small bile ducts. In recent years, reg-
ulatory T cells (Tregs) have been found to play a central
role in regulating T cell activation [2] and preventing
inflammation of the gastrointestinal tract [3,4]. A
relative deficiency of Tregs has been proposed to1Department of Medicine; 2Department of Pathology;
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6/j.bbmt.2010.09.015contribute to the uncontrolled inflammation of
GVHD in both mouse models [5-12] and humans
[13-18].
Tregs, which represent a small minority of CD41
Tcells, can be identified by their constitutive expression
of CD25 and by nuclear expression of the transcription
factor FOXP3 [19]. FOXP3 expression is necessary
and sufficient for T cells to differentiate into a Treg
phenotype [20,21], defined by the ability of these cells
to inhibit the proliferation, cytokine secretion, and
cytolytic activity of other T cells that they physically
contact [22,23]. Treg-mediated immune regulation ap-
pears to be particularly important in barrier organs such
as the gut, as mice engineered to specifically lack Tregs
[4,24] or humans born with FOXP3 mutations [3,25]
develop severe inflammation of the gut that resembles
gastrointestinal GVHD in humans.
Murine models of GVHD have elegantly demon-
strated that depletion of CD251 Tregs promotes
GVHD [8,12], whereas conversely, infusion of fresh
or in vitro expanded CD41CD251 Tregs can either
prevent or treat GVHD [5,9,11]. Prevention of
GVHD required that Tregs be of donor origin [7]
and express CD62L [6,10]. Treg infusions were able
to prevent murine GVHD without compromising
a desirable graft-versus-leukemia (GVL) effect [26-
28]. Thus, allogeneic donor Treg infusion could
represent an attractive way to treat or prevent GVHD
Table 1. Clinical Characteristics of Study Patients
Histological gastric GVHD Clinical GI GVHD
All Subjects Never At Least Once Never At Least Once
Total n 5 60 4 56 6 54
Median Range Median Range Median Range Median Range Median Range
Age 54 21-74 54 36-60 53 21-74 54 40-62 53 21-74
Day of GVHD onset n/a n/a n/a n/a 35 11-976 n/a n/a 36 11-986
n % n % n % n % n %
Males 35 58% 4 100% 31 55% 5 83% 30 56%
Myeloablative conditioning 46 77% 2 50% 44 79% 3 50% 43 80%
Donor:
Related 21 35% 0 0% 21 38% 1 17% 20 37%
Unrelated, HLA-matched 22 37% 1 25% 21 38% 2 33% 20 37%
Unrelated with HLA-mismatch 17 28% 3 75% 14 25% 3 50% 14 26%
Indication for HCT:
Acute leukemia 32 53% 2 50% 30 54% 3 50% 29 54%
Chronic leukemia 8 13% 1 25% 7 13% 0 0% 8 15%
Lymphoma 3 5% 1 25% 2 4% 1 17% 2 4%
Myeloma 3 5% 0 0% 3 5% 1 17% 2 4%
MDS 11 18% 0 0% 11 20% 0 0% 11 20%
Myelofibrosis 1 2% 0 0% 1 2% 0 0% 1 2%
Aplastic anemia 2 3% 0 0% 2 4% 1 17% 1 2%
Other GVHD sites:
Skin 25 42% 3 75% 22 39% 4 67% 18 33%
Liver 4 7% 0 0% 4 7% 0 0% 4 7%
GI GVHD prohylaxis:
CNI + MMF 20 33% 2 50% 18 32% 4 67% 16 30%
CNI + MTX 37 62% 1 25% 36 64% 2 33% 35 65%
CNI + MMF + Rapa 3 5% 1 25% 2 4% 0 0% 3 6%
GVHD indicates graft-versus-host disease; GI, gastrointestinal; HLA, human leucocyte antigen; HCT, hematopoietic cell transplant; MDS,myelodysplastic
syndrome; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; MTX, methotrexate; Rapa, rapamycin.
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Tregs in the peripheral blood of human HCT
recipients have been reported to be lower in the
presence than in the absence of acute GVHD
(aGVHD) [14,16,18]. Furthermore, a lower Treg
content in the blood or grafts of donors, prior to
infusion of donor cells, predicted the onset of GVHD
[13,15-17]. However, in chronic GVHD (cGVHD),
this correlation between increased Tregs and
decreased risk of GVHD has been absent [29,30] or
even reversed [31], although the latter study noted
that Tregs expressed less CD62L in the setting of
GVHD.
Most of the existing human studies have evaluated
Treg content only in the peripheral blood, and did not
focus specifically on gastrointestinal GVHD. How-
ever, only a very small fraction of peripheral blood
Tregs bear the gut-homing integrin a4b7 [32], and
thus, peripheral blood may not accurately reflect
Treg content in the gastrointestinal tract, where
GVHD might presumably be influenced by Tregs.
There have also been methodologic issues with some
earlier studies, including the use of ‘‘high’’ expression
levels of CD25 to identify Tregs, whichmust necessar-
ily be chosen arbitrarily and identifies acutely activated
T cells in addition to Tregs, as CD25 is up-regulated
by T cells upon activation [33]. In the study reported
here, we used an antibody recognizing the morespecific marker FOXP3 for immunohistochemistry
(IHC) and flow cytometry to identify Tregs in gastric
mucosa and peripheral blood, respectively, from
patients presenting for endoscopy with symptoms
suspicious for gastrointestinal GVHD. We tested the
hypothesis that histologic and endoscopic evidence
of GVHD was correlated with a decrease in the
number of Tregs in both gastrointestinal mucosa and
peripheral blood. Contrary to our expectation and
existing literature [5-18], we found that the fraction
of T cells that were Tregs was no lower in either the
peripheral blood or the gastric mucosa of allograft
recipients with GVHD than in those without.MATERIALS AND METHODS
Patient Selection
Under the aegis of a protocol approvedby the institu-
tional review board of the Fred Hutchinson Cancer
Research Center, allogeneic HCT recipients presenting
for endoscopic evaluation of gastrointestinal symptoms
consented to evaluation of their blood, gastrointestinal
mucosal tissue samples, and medical records. Subjects
withhuman immunodeficiencyvirus (HIV)or recurrence
ofmalignancy were excluded. Seventy-nine blood and/or
gastric biopsy specimens were obtained from 60 subjects,
46 having received myeloablative and 14 having received
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of the subjects (treating each specimen as an independent
subject) are summarized inTable 1. Indications for trans-
plant included hematologic malignancy (n 5 57, com-
prised of acute or chronic leukemia, myelodysplastic
syndrome, myeloma, or lymphoma), myelofibrosis (n 5
1), and aplastic anemia (n 5 2). Donors were related
and HLA-matched (n 5 21), or unrelated (n 5 39). Of
the unrelated donors, 22 were HLA-matched, and 17
mismatched.
Gastrointestinal GVHD Evaluation
Patient signs and symptoms were prospectively re-
corded by the physician performing the endoscopy. At
endoscopy, the presence or absence of focal abnormali-
ties and diffusemucosal pathologywere noted.One to 6
biopsies were taken each from the gastric antrum,
duodenum, and/or rectosigmoid colon with 2.9-3.2
mm radial cut cold biopsy forceps (Boston Scientific,
Boston, MA, USA). Biopsy specimens were placed in
fresh neutral-buffered formalin. Viral infections (cyto-
megalovirus [CMV] or adenovirus) were identified by
histology, centrifugation viral culture, and immunohis-
tology and Helicobacter pylori infections by histologic
stains and CLO test. Fixed tissue specimens were ori-
ented in paraffin blocks, serially sectioned at 4 mm,
stained with hematoxylin and eosin, and evaluated by
an experienced pathologist (R.C.H.) blinded to clinical,
endoscopy, and pathology information that had been re-
ported for clinical purposes.When both gastric and co-
lonic biopsy specimens were taken at the same
endoscopy session, specimens were evaluated indepen-
dently. A histologic diagnosis of GVHD was based on
the presence of apoptotic destruction of mucosal crypt
epithelial cells. A 4-tier grading system extends from
level I, in which individual apoptotic epithelial cells are
rare, to level IV, with extensive epithelial destruction as-
sociated with mucosal denudation, ulceration, hemor-
rhage, and granulation tissue formation [34,35].
Medical records were reviewed by a physician blinded
to FOXP3 data, in order to determine whether the
clinicians caring for a given patient treated the patient
for GVHD, what therapy was used, and how signs and
symptoms responded to treatment. If present, GVHD
was clinically considered ‘‘minimal’’ if symptoms
resolved with topical glucocorticoid medication alone
(oral beclomethasone dipropionate and/or enteric-
coated budesonide); ‘‘mild’’ if symptoms resolved with
1mg/kg/day prednisone or the equivalent dose ofmeth-
ylprednisolone; ‘‘moderate’’ if symptoms resolvedwith2
mg/kg/day of systemic glucocorticoids; and ‘‘severe’’ if
symptoms failed to respond to 2mg/kg/day prednisone.
Flow Cytometry of Blood Cells
Immediately prior to the endoscopy in 59 patients,
blood was taken from a central venous access line witha syringe and placed in a 10 mL heparin-containing
tube. Ten patients had blood collected at 2 different
times, and 1 patient had blood collected at 3 different
times, so that a total of 70 blood samples was evaluated.
Erythrocytes were lysed by calcium citrate, and resid-
ual leukocytes were stained extracellularly with
fluorophor-conjugated antibodies to CD4, CD8,
CD25, and CD62L (Becton Dickinson, San Jose,
CA, USA) before fixation and permeabilization with
a commercially available kit (eBioscience, San Diego,
CA, USA) for intracellular staining with fluorophor
conjugates of either an antibody to FOXP3 (clone
236A/E7, eBioscience) or an isotype-matched control
antibody. Cells were scanned with a Becton Dickinson
LSR2 flow cytometer, and data were evaluated with
FlowJo (Tree Star, Inc., Ashland, OR, USA) and
Graph Pad Prism (Graph Pad Software, Inc., San
Diego, CA, USA) software. All acquisition and pro-
cessing of flow cytometry data was performed by
researchers blinded to clinical and histologic data
IHC of Gastrointestinal Biopsy Specimens
Paraffin blocks, containing 1 to 6 formalin-fixed en-
doscopic biopsies of gastric antralmucosa each, were re-
trieved for 25 subjects, including 1 from whom blood
was not drawn Biopsies were evaluated at 2 or more
time points in 15 of these individuals, resulting in a total
of 43 independent evaluations. Sections were deparaffi-
nized and subjected to antigen retrieval in neutral pH
Target Retrieval Solution (DakoCytomation,Glostrup,
Denmark), blocked, and then stained with either
a monoclonal antibody to FOXP3 (clone 236A/E7,
eBioscience) in Background Reducing Antibody Dilu-
ent (DakoCytomation), or a polyclonal antiserum to
CD3 (CellMarque, Rocklin,CA,USA) inEDTA, using
the Envision1 kit (DakoCytomation) on an automated
immunostainer machine (DakoCytomation). Sections
were digitally photographed in their entirety at low
power, and images were processed with Photoshop
software (Adobe, Woodinville, WA, USA) to remove
obvious blemishes and nonspecific IHC reaction prod-
uct. Images were then analyzed with ImageJ software
(NIH, Bethesda, MD, USA) using a color deconvolu-
tion plugin to isolate DAB-stained cells and objectively
count the number of FOXP31 cells in each image.
Because CD31 cells are often too confluent to count
as independent image objects, the total number of pixels
staining positive for CD3 were quantified in each image
and divided by the average number of positive pixels
identified per CD31 cell in nonconfluent areas to
estimate CD31 T cell count. All staining and analysis
were performed by investigators blinded to clinical or
histologic data.
Statistical Analyses
The outcome measures described in the figure leg-
ends were compared between groups of interest using
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link function. This approach was required because of
the fact that some patients contributed multiple sam-
ples and the within-patient correlation therefore
needed to be accounted for in the estimation of the
variance of the difference in measures. If only 1 sample
were contributed per patient (as was the case for the
majority of patients), this approach would function
like an unpaired 2-sample t-test. All P values were for
2-sided analyses.RESULTS
Patient Characteristics
Six subjects were found to have viral gastritis
(n 5 5 for CMV, n 5 1 for adenovirus) at the time
of endoscopy as an explanation for their gastrointes-
tinal (GI) symptoms, and so were excluded from
GVHD1 cohorts. The remaining enrollees were de-
termined to have GI GVHD based upon either GI bi-
opsy histology (in the stomach and/or colon) or
whether the physicians treated GI GVHD. In the lat-
ter case, GVHD severity was classified based upon
patient response to treatment (see Materials and
Methods). Details of patient cohorts thus classified
are summarized in Table 1.Peripheral Blood Tregs in Patients with
Gastrointestinal GVHD
Flow cytometry revealed that FOXP3 expression
was restricted almost entirely to CD41 T cells, as ex-
pected, and correlated with CD25 expression, although
manyFOXP31 cells hadmoderate to lowCD25 expres-
sion (Figure 1A). Peripheral blood Tregs from subjects
in whom histologic evidence of GVHD was identified
in biopsies of stomach, rectosigmoid colon, both, or
neither were evaluated independently. We found the
percentage of CD41 T cells that were FOXP31 to be
no lower in the blood of subjects with histologic evi-
dence of gastrointestinal GVHD than in those without,
the latter group consisting of patients with either viral
(predominantly CMV) gastritis or no gastrointestinal
inflammation. In fact, significantly more blood CD41
cells were FOXP31 if histologic evidence of GVHD
was found in the stomach (P 5 .003) (Figure 1B). No
correlation was observed between blood FOXP31
Treg frequency and histological grade of GVHD sever-
ity in the upper or lower gastrointestinal tract, although
the vast majority of specimens were grade I (data not
shown).
Similarly, the percentage of CD41 cells in the
bloodstream expressing FOXP3 did not correlate with
clinical severity of gastrointestinal GVHD (as defined
by treatment-responsiveness in Methods), and a para-
doxically greater frequency of Tregs was identified inpatients with gastrointestinal GVHD than in those
without (P 5 .0004) (Figure 1C). These observations
were unchanged if we gated exclusively on cells that
expressed both FOXP3 andCD25 (data not shown). Al-
loreactive donorCD81 cytotoxicT lymphocytes (CTL)
are thought to play a central role in mediating tissue
damage in GVHD, so we additionally compared the
relative ratio of CD41, FOXP31 Tregs to CD81
CTL in these peripheral blood samples. However, the
ratio of FOXP31 toCD81 cells was again paradoxically
higher in patients with histologic (Figure 1D) or clinical
evidence of gastrointestinal GVHD (Figure 1E).
The presence of skinGVHDdid not influenceTreg
frequency (Figure 1F), regardless of whether patients
had histologic or clinical evidence of gastrointestinal
GVHD (data not shown). The shift in median fluores-
cent intensity between cells staining positive for
FOXP3 and cells stained with an isotype-matched con-
trol antibody was used to estimate relative FOXP3
expression per Treg, and this was likewise found to be
no lower in the presence than absence of histologic or
clinical evidence of GI GVHD (data not shown).
Inmousemodels, protection fromGVHDhas been
associated specifically with Tregs that express CD62L
(L-selectin) [6,10]. Therefore, we hypothesized that
fewer FOXP31 T cells would express CD62L in the
circulation of patients with gastrointestinal GVHD.
However, the percentage of blood FOXP31 T cells
expressing CD62L was actually significantly higher in
patients with histologic evidence of gastrointestinal
GVHD (P 5 .0004) (Figure 2A) than in those without.
A positive correlation betweenTregCD62L expression
and clinical evidence of gastrointestinalGVHDwas less
significant (P 5 .21) (Figure 2B), although the mean
percent of CD62L1 Tregs was clearly no lower in the
presence of GVHD. Thus, no quantitative deficiency
of peripheral blood Tregs, or their expression of
CD62L, was identified in GVHD.Mucosal Tregs in Patients with Gastrointestinal
GVHD
Gastric antral biopsies were evaluated for their Treg
content by IHC of serial sections for FOXP3 or CD3
(Figure 3A). We found the number of FOXP31 cells,
relative toCD31Tcells, was again paradoxically higher
ingastric biopsies of subjectswithgastricGVHDthan in
those without (P 5 .02) (Figure 3B). Gastric Treg fre-
quency did not drop in biopsies with a higher histologi-
cal grade of GVHD, but only 4 specimens were read as
higher than grade 1. Viral (predominantlyCMV) gastri-
tis was also associated with an increase in gastric
FOXP31 Treg frequency (P5 .02) (Figure 3B).
To test the hypothesis that Tregs may be seques-
tered from the blood into the mucosa in patients who
do not develop gastrointestinal GVHD, we compared
the ratio of blood to gastric Treg frequency between
Figure 1. Blood Tregs are not diminished in GVHD. (A) Representative plot of flow cytometric evaluation of blood, gated on live lymphocytes (left
panel), and then gated on either CD41 (upper panels) or CD81 (lower panels) T cells. For each specimen, 4-quadrant gates were set to exclude
.99% of cells stainedwith isotype control antibodies from positive quadrants (data not shown). (B) The percent of CD41 blood lymphocytes expressing
FOXP3 by fluorescence-activated cell sorting FACS is shown for patients with histologic evidence of GVHD in gastric biopsies (‘‘upper GI only’’), co-
lorectal biopsies (‘‘lowerGI only’’), or both (‘‘upper and lower’’) versus neither (‘‘none’’) or viral gastritis (CMVor adenovirus). The difference between all
cases with versus without histologic evidence of GVHD in the stomach was analyzed to generate the P value shown. (C) FOXP3 expressing CD41 lym-
phocytes were compared as in B between patients with varying clinical severity of GI GVHD, defined as described in Materials and Methods. All patients
with any clinical evidence of GI GVHDwere pooled for comparison with patients without clinical GI GVHD or with viral gastritis to generate the P value
shown. (D, E) The ratio of blood FOXP31 lymphocytes to CD81 lymphocytes, determined by FACS, was compared between the cohorts described in B
and C. (F) FOXP3 expressing CD41 lymphocytes were compared as in B between patients with versus without clinical evidence of skin GVHD.
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Figure 2. Blood Treg CD62L expression is not decreased in GVHD.
(A) The percent of FOXP31 lymphocytes expressing CD62L by FACS
was compared between patients with versus without histologic evidence
of gastrointestinal GVHD. (B) CD62L expression among FOXP31
lymphocytes was compared between patients with versus without any
clinical evidence of GI GVHD, as described in Materials and Methods.
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whom both blood and mucosal biopsies had been ana-
lyzed at the same time. Treg frequency was defined as
the percentage of total T cells (T cells defined as
CD31 cells in mucosal biopsies, and the sum of
CD41 and CD81 cells in peripheral blood) that ex-
pressed FOXP3. Evaluating all patients together, therewas no correlation, positive or negative, between the
percentage of T cells expressing FOXP3 in the gastric
mucosa versus blood (r25 .001264, P5 .8369). There
appeared to be more sequestration of FOXP31 Tregs
from blood to gastric mucosa in the few patients
analyzed with viral gastritis than in patients without
virus or gastric GVHD (P 5 .0004). However, when
viral gastritis patients were removed from the GVHD-
negative cohort, the ratio of blood to mucosal Treg
frequency did not correlate with the presence of gas-
trointestinal GVHD, defined either histologically or
clinically (Figure 3C).Tregs Do Not Correlate with Patient
Demographics, Transplant Characteristics,
or Medications
As this was a small observational study, there was
necessarily considerable heterogeneity between patient
comparison groups (see Table 1), raising the possibility
that Treg frequency could be correlating with a charac-
teristic other than the presence or absence of GI
GVHD, so we tested a variety of potential confounders.
By univariate analyses, we did not find subject age, sex,
HCT indication, conditioning regimen, donor rela-
tionship, or time interval post-HCT to correlate with
Treg frequency in either blood or mucosal biopsies
(data not shown). Whether or not patients were taking
a calcineurin inhibitor (CNI), mycophenolate mofetil
(MMF), or a glucocorticoid (either systemic or
GI-specific) at the time of specimen acquisition had
no effect on FOXP31 Treg frequency in the blood
(Figure 4A). A trend toward decreased gastric mucosal
Tregs was noted in patients on any of the above
(Figure 4B), but this was only significant for MMF
(P 5 .03). Previous use of systemic steroids post-HCT
did not impact the blood or gastric FOXP31 T cell
frequency at the time of sampling (data not shown).
CD31 peripheral blood chimerism studies had
been performed within 30 days of sampling for 32 of
the 79 blood and/or gastric biopsy specimens used for
this study; 8 with reduced intensity conditioning
(RIC), and 24 with myeloablative conditioning. Eigh-
teen of these 32 specimens (and 5 specimens from
RIC patients) were obtained when there were .90%
donorTcells in theperipheral blood, soonly aminority
of subjects had a significant number of recipient T cells
still present at the time of sampling. When compared
between subjects with versus without histologic evi-
dence of gastric GVHD, there was a nonsignificant
trend toward more complete engraftment in patients
with GVHD (P 5 .1064). We also performed linear
regression analyses of blood and gastric FOXP31 cells
versus chimerism, both for RIC and myeloablative
regimen recipients, and found no significant correla-
tions (data not shown).
Figure 3. Gastric mucosal Tregs are not decreased in GVHD. (A) Representative histology of gastric biopsies from patients with (right panels) versus
without (left panels) gastric GVHD, stained immunohistochemically for FOXP3 (upper panels) or CD3 (lower panels). (B) The FOXP31 to CD31 ratio
(expressed as a percentage) of serial sections of gastric biopsies was compared based upon the histological grade of GVHD severity within those bi-
opsies. P value shown is for comparison between pooled specimens with grade I-IV GVHD, versus specimens with no GVHD (‘‘none’’) or viral gastritis.
(C) The percentage of T cells expressing FOXP3 (per CD31 cells in gastric biopsies, and per pooled CD41 and CD81 in blood) was expressed as a ratio
between blood and biopsies, and compared between patients with or without histologic evidence of gastric GVHD (middle) or clinical evidence of GI
GVHD (right), or between patients with viral gastritis versus no histologic evidence of gastric GVHD (left).
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Figure 4. Tregs are not increased by immunosuppressant drugs. The percentage of CD41 cells in blood expressing FOXP3 (A) or of CD31 cells in
gastric mucosa expressing FOXP3 (B) was compared between patients who were versus were not on a calcineurin inhibitor (CNI; tacrolimus or cyclo-
sporine), mycophenolatemofetil (MMF), prednisone/methylprednisolone (Pred), or a combination of oral budesonide and beclomethasone dipropionate
(BDP) at the time of biopsy.
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The principal findings of this prospective study
were that FOXP31 regulatory T cells in patients
with upper gut aGVHD were at least as common in
both the peripheral blood and gastric mucosa as in pa-
tients without GVHD. That is, in contrast to a body of
literature supporting a pivotal role for Tregs in limit-
ing, preventing, or reversing GVHD in mice, our
data do not indicate that a dearth of total FOXP31
Tregs contributes to the pathogenesis of upper gut
GVHD in humans. The technology employed in this
study cannot exclude the possibility that a small sub-
population of these Tregs, perhaps with specificityto a certain antigen or allo-MHC, is depleted in
GVHD. Furthermore, determining whether these
Tregs developed a functional defect in GVHD was
outside the scope of this study. Similarly, we cannot ex-
clude the possibility that a difference in the source of
Tregs (donor versus recipient) correlates with
GVHD, although this possibility would be unlikely
in the peripheral blood of HCT recipients who under-
went myeloablative conditioning, or otherwise were
noted to have donor chimerism at or near 100% in
their peripheral CD31 cells. Indeed, in a subset of pa-
tients who were evaluated for donor–host chimerism
within 30 days of study specimen acquisition, we found
chimerism of CD31 T cells to correlate with neither
494 Biol Blood Marrow Transplant 17:486-496, 2011J. D. Lord et al.the presence of GVHD nor Treg frequency at any
anatomic site evaluated (data not shown).
A number of differences between our study and ex-
isting reports enumerating peripheral blood Tregs in
human GVHD may explain why we do not find an in-
verse correlation between GVHD and Treg frequency
in the blood. First, our study focused primarily upon
the gastrointestinal tract for the presence of GVHD,
and cannot exclude a possible correlation between
Tregs and GVHD involving the skin and liver. How-
ever, a substantial fraction of our subjects did have
skinGVHD, with which bloodTregs showed no corre-
lation (Figure 1E). Second, our subjects underwent ini-
tial phlebotomy and mucosal biopsy at the point of
GVHD diagnosis, after the onset of symptoms and, in
most cases, before the administration of systemic
corticosteroids. For studies that reported a decreased
Treg frequency subsequent to GVHD diagnosis
[13,14,16,18,36], it is possible that treatment of
GVHD, particularly with systemic corticosteroids,
altered Treg frequency relative to subjects without
GVHD, although we did not see such an effect. Some
of these studies reported a decreased Treg frequency
in HCT donors or grafts or in the blood of recipients
prior to GVHD onset. Therefore, it is possible that
a decreased frequency of Tregs preceded the onset of
clinical GVHD in our subjects, but was no longer
evident by the time symptoms developed.
As noted previously, differences between our data
and the existing literature may also reflect differences
in theway thatTregswere identified.Manyof the earlier
studies ofTregs inGVHD,whichwere performed prior
to the widespread availability of antibodies capable of
recognizing FOXP3, instead used an arbitrarily high
level ofCD25 expression as amarker forTregs in a pop-
ulation of CD41 T cells [18,37,38]. We find that only
a fraction of FOXP31 cells express exceptionally high
levels of CD25 (Figure 1A), making this marker fairly
insensitive for FOXP31 cells. Furthermore, CD25 ex-
pression is induced in all activated T cells, including
FOXP32 cells, making this marker potentially nonspe-
cific in the setting of acute inflammation. Some previous
studies therefore corroborated CD25 data with FOXP3
mRNA expression levels [14,39]. However, mRNA
assays cannot differentiate low expression in a large
fraction of cells from high expression in a small
fraction of cells, and additionally may not accurately
reflect protein expression. A more recent flow
cytometric analysis of CD41, CD251, FOXP31 cells
in the blood of HCT recipients with versus without
aGVHD found no difference in relative Treg content,
and additionally demonstrated that these Tregs are
functional, with in vitro inhibitory activity against
other T cells [40].
Finally, almost all studies on Tregs in human
GVHD have evaluated these cells exclusively in the
peripheral blood. Only one study evaluated Tregs incolonic mucosa, finding an increased Treg frequency
in HCT recipients who did not develop gastrointesti-
nal GVHD relative to those who did, or to healthy
controls [36]. However, the majority of patients in
this study were on systemic corticosteroids at the
time of biopsy, which may have altered results. We
report the first evaluation of Treg frequency in the gas-
tric mucosa of HCT recipients, with the most com-
mon presentation of GVHD, that involving the
upper gut [41]. Even in patients whose GVHD pres-
ents with diarrhea, there is more prominent apoptosis
of epithelial cells in the bases of crypts in the gastric
mucosa than in the colon [42], suggesting that the
stomach may be the more active area of alloreactivity
in the GI tract, and hence, a more sensitive organ in
which to detect any deficiency in Tregs that might ac-
company GVHD. Although a higher density of lym-
phocytes exists in the mid to distal small bowel, and
might therefore be an even more representative mu-
cosa in which to study GVHD, this area is not easily
accessible with endoscopic biopsy.
Our observation that Tregs are increased in the set-
ting of gastric GVHD seems counterintuitive, given the
inhibitory role that FOXP31 cells have been shown to
have in mice. One difference between FOXP3 expres-
sion in mice and humans is that it can be induced de
novo in most CD41T cells by in vitro activation in hu-
mans in the absence of exogenous transforming growth
factor (TGF)-b [43-46]. Therefore, the increased
number of FOXP31 T cells we have observed in
GVHD may simply reflect acutely activated T cells.
Consequently, the highest frequency of Tregs was
seen in patients with both gastric and colonic GVHD
(Figure 1B), perhaps reflecting a greater degree of sys-
temic T cell activation in this population. Although
some authors have found such activation-induced
FOXP3 expression to confer no inhibitory activity
[43], others have reported that so-called ‘‘induced
Tregs’’ have in vitro immunoinhibitory activity similar
to Tregs that stably express FOXP3 [44-46],
suggesting that both types of FOXP31 T cells may be
important for downregulating inflammation. It is
unclear why they would fail to do so in GVHD, but
there may be differences between the in vitro and in
vivo inhibitory potential of induced FOXP31 T cells.
We conclude that upper gastrointestinal GVHD is
not correlated with a global dearth of FOXP31 Tregs
in humans, in either the peripheral blood or gastric
mucosa, at the time of symptomatic presentation.
Consequently, enumeration of Tregs in these areas is
unlikely to be of diagnostic or prognostic utility in
the evaluation of upper gastrointestinal symptoms sus-
picious for GVHD. Our data also suggest that thera-
peutic infusion of Tregs may have limited efficacy in
the treatment of established gastrointestinal GVHD,
as the Tregs already present in patients with this disor-
der fail to inhibit mucosal inflammation. Indeed, the
Biol Blood Marrow Transplant 17:486-496, 2011 495FOXP3+ T Cells Are Not Decreased in Gastric GVHDfirst published case reports of in vitro expanded Treg
infusion in human HCT recipients were recently pub-
lished [47], and demonstrated no efficacy in a patient
with severe aGVHD, although their infusion may
have had some effect in one with cGVHD. Future
studies are needed to determine whether there is a dif-
ference in the source (donor versus recipient) or allor-
eactivity of the Tregs present in patients with GVHD,
in which case selective enrichment of Tregs with
whichever characteristic is deficient in GVHD may
provide a greater chance of therapeutic success. Alter-
natively, there may be conditions in the intestinal mi-
croenvironment of patients with gastrointestinal
GVHD that impair the inhibitory function of Tregs,
regardless of their specificity, source, or number. In-
deed, ample numbers of intramucosal Tregs also exist
in inflammatory bowel disease [48,49], and have intact
intrinsic inhibitory function in vitro [50], yet fail to
control mucosal inflammation in vivo. Perhaps there
are conditions within the intestinal microenvironment
that impair their inhibitory function in IBD, which
may also be relevant in gastrointestinal GVHD.ACKNOWLEDGMENTS
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